Showing 6711-6720 of 8238 results for "".
- Incyte's Opzelura is First Topical JAK Inhibitor Approved in UShttps://practicaldermatology.com/news/incyts-opzelura-is-first-topical-jak-inhibitor-approved-in-us/2460919/Opzelura™ (ruxolitinib) cream from Incyte is now the first and only topical formulation of a JAK inhibitor approved in the United States. FDA approved Opzelura for the short-term and non-continuous chronic treatment of mild-to-moderate atopic dermatitis
- Accure Acne, Inc. Appoints Jeffrey O'Donnell, Sr. to the Boardhttps://practicaldermatology.com/news/accure-acne-inc-announces-the-appointment-of-jeffrey-odonnell-sr-to-the-board/2460918/Jeffrey O'Donnell, Sr. has joined Accure Acne's Board of Directors. Along with Chairman and Founder Christopher Carlton and Founder Ed Barbera, Mr. O'Donnell provides strategic guidance for Accure's i
- NPF Task Force Issues New Guidance on COVID-19 Vaccine Boosters for PsO Patientshttps://practicaldermatology.com/news/npf-task-force-issues-new-guidance-on-covid-19-vaccine-boosters-for-pso-patients/2460911/The Centers for Disease Control and Prevention (CDC) recently released new information on COVID-19 vaccines for moderately to severely immunocompromised people. Since these individuals may be especially vulnerable to COVID-19, due to their increased
- Public Citizen to FDA: Pull Propecia from the Markethttps://practicaldermatology.com/news/public-citizen-to-fda-pull-propecia-from-the-market/2460908/Public Citizen today filed a lawsuit on behalf of the Post-Finasteride Syndrome Foundation (PFSF) against the U.S. Food and Drug Administration (FDA) fo
- Study: UV Exposure Produces Epigenetic Changes in the Epidermis to Induce Skin Pigmentationhttps://practicaldermatology.com/news/study-uv-exposure-produces-epigenetic-changes-in-the-epidermis-to-induce-skin-pigmentation/2460905/Exposure to the sun's ultraviolet (UV) rays produces epigenetic changes in the epidermis to induce skin pigmentation, a new study shows. UV exposure causes DNA damage in epidermal cells and is a leading cause of skin cancers. To protect from the damaging effects of UV exposure, epid
- FDA: Omeza's Collagen Matrix Cleared for Marketinghttps://practicaldermatology.com/news/fda-omezas-collagen-matrix-cleared-for-marketing/2460904/The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to the Omeza Collagen Matrix for chronic wound care. Omeza Collagen Matrix (OCM) is a wound care matrix comprised of hydrolyzed fish collagen infused with cod liver oil, which acts as an anhydrous skin pr
- New Melanoma Staging System May Better Predict Prognosishttps://practicaldermatology.com/news/new-melanoma-staging-system-may-better-predict-prognosis/2460901/A new system for classifying melanoma when the disease has spread to the lymph nodes may offer a better tool for predicting patients' outcomes and determining their treatment needs, according to research in
- Business News: Crown Labs to Acquire StriVectinhttps://practicaldermatology.com/news/business-news-crown-labs-acquire-strivectin/2460897/Crown Laboratories is slated to acquire StriVectin from the private equity firm L Catterton. The transaction is expected to close by mid-September and is subject to regulatory approvals and other customary closing conditions. Terms of the transaction were not disclosed.
- Experts Call for Greater Attention to Persistent Redness of Rosaceahttps://practicaldermatology.com/news/experts-call-for-greater-attention-to-persistent-redness-of-rosacea/2460896/Dermatologists should place greater emphasis on persistent facial erythema of rosacea, a panel of experts concludes. Their recommendations, based on a National Rosacea Society (NRS) roundtable conversation, appear in the <
- Lilly's Lebrikizumab Performs Well in Two Phase 3 AD Trialshttps://practicaldermatology.com/news/lillys-lebrikizumab-performs-well-in-two-phase-3-ad-trials/2460892/Eli Lilly and Company's lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), according to top-line results from ADvocate 1 and ADvocate 2. All primary and all key secondary en